Cargando…
Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
Fingolimod was recently approved for use in the United States after two phase III trials confirmed its effectiveness in reducing disease activity in relapsing-remitting multiple sclerosis. These positive results, coupled with the important fact that this is the first oral disease-modifying therapy,...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663606/ https://www.ncbi.nlm.nih.gov/pubmed/23861637 http://dx.doi.org/10.4137/JCNSD.S5120 |